Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
19 results
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey
D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation
D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report
D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months
D1.391 - Pharmacist-led Risk-based β-Lactam Challenges in Patients with Penicillin Allergy: Impact on Antibiotic Days
D1.381 - Antibiotic Allergy De-labelling in Children: Outcomes of Drug Provocation Testing and Feasibility of Non-Specialist Pathways to de-labelling
D1.382 - Vitamin K–Induced Anaphylaxis: A Case Series from a Tertiary Hospital in Manila, Philippines (2024–2025)
D1.384 - Safe Sulfonamide Delabeling in HIV-Negative Adults: Real-World Evidence with TMP-SMX Oral Challenge and SULF-FAST
D1.385 - Lamotrigine-induced Stevens-Johnson syndrome in a pediatric patient with Takayasu arteritis: the steroid paradox
D1.387 - Long-term Follow-up Outcomes of Patients Undergoing Desensitization for Non-Immediate Hypersensitivity Reactions Associated with Lenalidomide
D1.388 - Aspirin maintenance after boost with dupilumab in aspirin-exacerbated respiratory disease
D1.390 - Hypersensitivity Reactions to Biological Agents in a Tertiary Hospital: A 3.5-Year Retrospective Study
D1.392 - Drug-Induced Hypersensitivity Syndrome Associated with β-Lactams and Hemophagocytic Lymphohistiocytosis: Overlapping Disorders or a Causal Relationship?
D1.393 - Safety of Aspirin Oral Provocation in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Download the app
The congress at your fingertips
Available on
Download